Association of tamoxifen biliary excretion rate with prior tamoxifen exposure and increased mdr1b expression

Biochemical Pharmacology

Volumn 60, Issue 2, 2000, Pages 233-239

  Riley, Joan ^a   Styles, Jerry ^a   Verschoyle, Richard D ^a   Stanley, Lesley A ^a   White, Ian N H ^a   Gant, Timothy W ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Biliary excretion; Gene expression; Multidrug resistance; RT PCR; Tamoxifen

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN; TAMOXIFEN;

ANIMAL EXPERIMENT; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DIET; DRUG EXCRETION; DRUG METABOLISM; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BILE CANALICULI; GENE EXPRESSION; LIVER; METABOLIC CLEARANCE RATE; P-GLYCOPROTEIN; RATS; RATS, INBRED LEW; TAMOXIFEN;

EID: 0034662469     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00326-9     Document Type: Article

References (49)

1. Jordan V.C. Overview from the International Conference on Long-Term Tamoxifen Therapy for Breast Cancer. J Natl Cancer Inst. 84:1992;231-234.
2. Fisher B., Costantino J.P., Redmond C.K., Fisher E.R., Wickerham D.L., Cronin W.M. Endometrial cancer in tamoxifen-treated breast cancer patients Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 86:1994;527-537.
3. White I.N. The tamoxifen dilemma. Carcinogenesis. 20:1999;1153-1160.
4. Rutqvist L.E. Re Second cancers after tamoxifen therapy for breast cancer. J Natl Cancer Inst. 88:1996;1497-1499.
5. Carmichael P.L., Ugwumadu A.H., Neven P., Hewer A.J., Poon G.K., Phillips D.H. Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res. 56:1996;1475-1479.
6. Shibutani S., Suzuki N., Terashima N., Sugarman S.M., Grollman A.P., Pearl M.A. Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen. Chem Res Toxicol. 12:1999;646-653.
7. Hemminki K., Rajaniemi H., Lindahl B., Moberger B. Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res. 56:1996;4374-4377.
8. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., Vogel V., Robidoux A., Dimitrov N., Atkins J., Daly M., Wieand S., Tan-Chiu E., Ford L., Wolmark N. Tamoxifen for prevention of breast cancer. J Natl Cancer Inst. 90:1998;1371-1388.
9. Fromson J.M., Pearson S., Bramah S. The metabolism of tamoxifen (I.C.I. 46, 474). I. In laboratory animals. Xenobiotica. 3:1973;693-709.
10. Lien E.A., Solheim E., Lea O.A., Lundgren S., Kvinnsland S., Ueland P.M. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res. 49:1989;2175-2183.
11. Lien E.A., Kvinnsland S., Ueland P.M. Identification of 4-hydroxydesmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res. 48:1988;2304-2308.
12. Boocock D.J., Maggs J.L., White I.N., Park B.K. Alpha-hydroxytamoxifen, a genotoxic metabolite of tamoxifen in the rat Identification and quantification in vivo and in vitro. Carcinogenesis. 20:1999;153-160.
13. Lien E.A., Solheim E., Ueland P.M. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res. 51:1991;4837-4844.
14. Greenberger L.M., Lothstein L., Williams S.S., Horwitz S.B. Distinct P-glycoprotein precursors are overproduced in independently isolated drug-resistant cell lines. Proc Natl Acad Sci USA. 85:1989;3762-3766.
15. Ueda K., Cardarelli C., Gottesman M.M., Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA. 84:1987;3004-3008.
16. Choi K., Frommel T.H., Stern R.K., Perez C.F., Kriegler M., Tsuruo T., Roninson I.B. Multidrug resistance after retroviral transfer of the human MDR1 gene correlates with P-glycoprotein density in the plasma membrane and is not affected by cytotoxic selection. Proc Natl Acad Sci USA. 88:1991;7386-7390.
17. Buschman E., Gros P. The inability of the mouse mdr2 gene to confer multidrug resistance is linked to reduced drug binding to the protein. Cancer Res. 54:1994;4895-4898.
18. Croop J.M., Raymond M., Haber D., Devault A., Arceci R.J., Gros P., Housman D.E. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol. 9:1989;1346-1350.
19. Smit J.J., Schinkel A.H., Oude Elferink R.P., Groen A.K., Wagenaar E., van Deemter L., Mol C.A., Ottenhoff R., van der Lugt N.M., van Roon M.A., van der Valk M.P., Offerhaus G.J., Berns A.J., Borst P. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell. 75:1993;451-462.
20. van Asperen J., Schinkel A.H., Beijnen J.H., Nooijen W.J., Borst P., van Tellingen O. Altered pharmacokinetics of vinblastine in mdr1a P-glycoprotein-deficient mice. J Natl Cancer Inst. 88:1996;994-999.
21. Schinkel A.H., Mayer U., Wagenaar E., Mol C.A., van Deemter L., Smit J.J., van der Valk M.A., Voordouw A.C., Spits H., van Tellingen O., Zijlmans J.M., Fibbe W.E., Borst P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA. 94:1997;4028-4033.
22. Schinkel A.H., Smit J.J., van Tellingen O., Beijnen J.H., Wagenaar E., van Deemter L., Mol C.C., van der Valk M.A., Robanus-Maandag E.C., te Riele H.P., Berns A.J., Borst P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 77:1994;491-502.
23. Sparreboom A., van Asperen J., Mayer U., Schinkel A.H., Smit J.W., Meijer D.K., Borst P., Nooijen W.J., Beijnen J.H., van Tellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA. 94:1997;2031-2035.
24. Fardel O., Lecureur V., Corlu A., Guillouzo A. P-glycoprotein induction in rat liver epithelial cells in response to acute 3-methylcholanthrene treatment. Biochem Pharmacol. 51:1996;1427-1436.
25. Gant T.W., Silverman J.A., Bisgaard H.C., Burt R.K., Marino P.A., Thorgeirsson S.S. Regulation of 2-acetylaminofluorene- and 3-methylcholanthrene-mediated induction of multidrug resistance and cytochrome P450IA gene family expression in primary hepatocyte cultures and rat liver. Mol Carcinog. 4:1991;499-509.
26. Silverman J.A., Raunio H., Gant T.W., Thorgeirsson S.S. Cloning and characterization of the rat multidrug resistance (mdr) gene family. Gene. 106:1991;229-236.
27. Fairchild C.R., Ivy S.P., Rushmore T., Lee G., Koo P., Goldsmith M.E., Myers C., Farber E., Cowan K.H. Carcinogen-induced mdr overexpression is associated with xenobiotic resistance in rat preneoplastic liver nodules and hepatocellular carcinomas. Proc Natl Acad Sci USA. 84:1987;7701-7705.
28. Schrenk D., Gant T.W., Preisegger K.H., Silverman J.A., Marino P.A., Thorgeirsson S.S. Induction of multidrug resistance gene expression during cholestasis in rats and nonhuman primates. Hepatology. 17:1993;854-860.
29. Gant T.W., O'Connor C.K., Corbitt R., Thorgeirsson U., Thorgeirsson S.S. In vivo induction of liver P-glycoprotein expression by xenobiotics in monkeys. Toxicol Appl Pharmacol. 133:1995;269-276.
30. Wacher V.J., Wu C.Y., Benet L.Z. Overlapping substrate specificities and tissue distribution of cytochrome p450 3A and P-glycoprotein Implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog. 13:1995;129-134.
31. Schuetz E.G., Beck W.T., Schuetz J.D. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 49:1996;311-318.
32. 32P-postlabelling in three rat strains exposed to dietary tamoxifen The relationship between cell proliferation and liver tumour formation. Carcinogenesis. 16:1995;1299-1304.
33. Zhang F., Riley J., Gant T.W. Use of internally controlled RT-PCR for absolute quantitation of individual multidrug resistant gene transcripts in tissue samples. Electrophoresis. 17:1996;255-260.
34. Callaghan R., Higgins C.F. Interaction of tamoxifen with the multidrug resistance P-glycoprotein. Br J Cancer. 71:1995;294-299.
35. Kirk J., Syed S.K., Harris A.L., Jarman M., Roufogalis B.D., Stratford I.J., Carmichael J. Reversal of P-glycoprotein-mediated multidrug resistance by pure anti-oestrogens and novel tamoxifen derivatives. Biochem Pharmacol. 48:1994;277-285.
36. Rao U.S., Fine R.L., Scarborough G.A. Antiestrogens and steroid hormones Substrates of the human P-glycoprotein. Biochem Pharmacol. 48:1994;287-292.
37. Pommerenke E., Mattern J., Volm M. Modulation of doxorubicin-toxicity by tamoxifen in multidrug-resistant tumor cells in vitro and in vivo. J Cancer Res Clin Oncol. 120:1994;422-426.
38. Kirk J., Houlbrook S., Stuart N.S., Stratford I.J., Harris A.L., Carmichael J. Selective reversal of vinblastine resistance in multidrug-resistant cell lines by tamoxifen, toremifene and their metabolites. Eur J Cancer. 29A:1993;1152-1157.
39. Kang Y., Perry R.R. Modulatory effects of tamoxifen and recombinant human alpha-interferon on doxorubicin resistance. Cancer Res. 53:1993;3040-3045.
40. Berman E., Adams M., Duigou-Osterndorf R., Godfrey L., Clarkson B., Andreeff M. Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype. Blood. 77:1991;818-825.
41. Spoelstra E.C., Westerhoff H.V., Pinedo H.M., Dekker H., Lankelma J. The multidrug-resistance-reverser verapamil interferes with cellular P-glycoprotein-mediated pumping of daunorubicin as a non-competing substrate. Eur J Biochem. 221:1994;363-373.
42. McCague R., Parr I.B., Leclercq G., Leung O.T., Jarman M. Metabolism of tamoxifen by isolated rat hepatocytes. Identification of the glucuronide of 4-hydroxytamoxifen. Biochem Pharmacol. 39:1990;1459-1465.
43. 14C]tamoxifen to liver microsomes and the forms of cytochrome P450 involved. Biochem Pharmacol. 49:1995;1035-1042.
44. Jedlitschky G., Leier I., Buchholz U., Barnouin K., Kurz G., Keppler D. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res. 56:1996;988-994.
45. Loe D.W., Almquist K.C., Cole S.P., Deeley R.G. ATP-dependent 17 beta-estradiol 17-(beta-D-glucuronide) transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids. J Biol Chem. 271:1996;9683-9689.
46. Kauffmann H.M., Keppler D., Gant T.W., Schrenk D. Induction of hepatic mrp2 (cmrp/cmoat) gene expression in nonhuman primates treated with rifampicin or tamoxifen. Arch Toxicol. 72:1998;763-768.
47. Buchler M., Konig J., Brom M., Kartenbeck J., Spring H., Horie T., Keppler D. cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J Biol Chem. 271:1996;15091-15098.
48. Kool M., de Haas M., Scheffer G.L., Scheper R.J., van Eijk M.J., Juijn J.A., Baas F., Borst P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 57:1997;3537-3547.
49. Trump D.L., Smith D.C., Ellis P.G., Rogers M.P., Schold S.C., Winer E.P., Panella T.J., Jordan V.C., Fine R.L. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent Phase I trial in combination with vinblastine. J Natl Cancer Inst. 84:1992;1811-1816.